UY26918A1 - 7 - PIRIDOPIRIMIDIN OXY (II) - Google Patents

7 - PIRIDOPIRIMIDIN OXY (II)

Info

Publication number
UY26918A1
UY26918A1 UY26918A UY26918A UY26918A1 UY 26918 A1 UY26918 A1 UY 26918A1 UY 26918 A UY26918 A UY 26918A UY 26918 A UY26918 A UY 26918A UY 26918 A1 UY26918 A1 UY 26918A1
Authority
UY
Uruguay
Prior art keywords
disease
piridopirimidin
oxy
crohn
alzheimer
Prior art date
Application number
UY26918A
Other languages
Spanish (es)
Inventor
J P Dunn
D M Goldstein
J J Chen
J A Lim
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY26918A1 publication Critical patent/UY26918A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula: 1 en la que R1, R2, R3 y Ar1 tienen los significados definidos en la invención, y a métodos de obtención y a su utilización para el tratamiento de trastornos causados por p38, p.ej. el método de la reivindicación 26 o 27, en el que dicho trastorno causado por p38 se selecciona entre la artritis, la enfermedad de Crohn, la enfermedad de Alzheimer, el síndrome de intestino irritable, el síndrome de la deficiencia respiratoria adulta y la enfermedad pulmonar obstructiva crónica.The present invention relates to compounds of the formula: 1 in which R1, R2, R3 and Ar1 have the meanings defined in the invention, and methods of obtaining them and their use for the treatment of disorders caused by p38, e.g. the method of claim 26 or 27, wherein said disorder caused by p38 is selected from arthritis, Crohn's disease, Alzheimer's disease, irritable bowel syndrome, adult respiratory deficiency syndrome and lung disease chronic obstructive

UY26918A 2000-08-31 2001-08-30 7 - PIRIDOPIRIMIDIN OXY (II) UY26918A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22958400P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
UY26918A1 true UY26918A1 (en) 2002-02-28

Family

ID=22861859

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26918A UY26918A1 (en) 2000-08-31 2001-08-30 7 - PIRIDOPIRIMIDIN OXY (II)

Country Status (15)

Country Link
EP (1) EP1315726A1 (en)
JP (1) JP4141830B2 (en)
KR (1) KR100571339B1 (en)
CN (1) CN1275964C (en)
AR (1) AR033681A1 (en)
AU (2) AU9378401A (en)
BR (1) BR0113628A (en)
CA (1) CA2420286A1 (en)
GT (1) GT200100191A (en)
MX (1) MXPA03001821A (en)
PA (1) PA8527301A1 (en)
PE (1) PE20020406A1 (en)
UY (1) UY26918A1 (en)
WO (1) WO2002018380A1 (en)
ZA (1) ZA200301079B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001733A (en) * 2000-08-31 2003-05-27 Hoffmann La Roche 7-oxo pyridopyrimidines.
US6518276B2 (en) 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
CA2479644A1 (en) * 2002-04-03 2003-10-09 F. Hoffmann-La Roche Ag Imidazo fused compounds
AU2003225072A1 (en) * 2002-04-19 2003-11-03 Smithkline Beecham Corporation Novel compounds
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
UY27939A1 (en) 2002-08-21 2004-03-31 Glaxo Group Ltd COMPOUNDS
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
AU2003283393A1 (en) * 2002-11-18 2004-06-15 F. Hoffmann-La Roche Ag Diazinopyrimidines
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2006522756A (en) 2003-04-10 2006-10-05 エフ．ホフマン−ラ　ロシュ　アーゲー Pyrimido compounds
US20070020234A1 (en) * 2003-07-07 2007-01-25 Vande Woude George F Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
EP1685131B1 (en) * 2003-11-13 2007-03-07 F. Hoffmann-La Roche AG Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
WO2005105097A2 (en) * 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20090131430A1 (en) * 2004-11-23 2009-05-21 Palle Venkata P Pyrido'2,3-dipyrimidines as anti-inflammatory agents
EP1846403A1 (en) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Azabicyclo derivatives as anti-inflammatory agents
EP1931667A1 (en) * 2005-09-28 2008-06-18 Ranbaxy Laboratories Limited Pyrido-pyridimidine derivatives useful as antiinflammatory agents
KR20080083046A (en) 2006-01-31 2008-09-12 에프. 호프만-라 로슈 아게 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
KR100661523B1 (en) * 2006-06-09 2006-12-26 주식회사 청용산기 Box correcting device of stitching progress for carton box erecting
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JP2010509265A (en) 2006-11-09 2010-03-25 エフ．ホフマン−ラ ロシュ アーゲー Substituted 6-phenyl-pyrido [2,3-D] pyrimidin-7-one derivatives as kinase inhibitors and methods of use thereof
WO2008078249A1 (en) * 2006-12-21 2008-07-03 Ranbaxy Laboratories Limited Anti-inflammatory agents
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
KR101106162B1 (en) * 2010-04-20 2012-01-20 주식회사 청용산기 Stitching device for packing box making apparatus
CA2868156C (en) * 2012-03-22 2020-07-28 Genosco Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
TWI647220B (en) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 Heteroaryl compound and its use
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
SG11201507478VA (en) 2013-03-15 2015-10-29 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
US10280162B2 (en) 2014-09-12 2019-05-07 Biolab Sanus Farmaceutica Ltda Pyridopyrimidines derivatives compounds
CA3077499C (en) 2017-10-05 2021-09-21 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2020142612A1 (en) * 2019-01-03 2020-07-09 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
EP3976611A1 (en) * 2019-05-31 2022-04-06 Les Laboratoires Servier Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
WO2022052924A1 (en) * 2020-09-11 2022-03-17 上海凌达生物医药有限公司 Preparation method for class of nitrogen-containing fused ring compounds and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD1861G2 (en) * 1994-11-14 2002-09-30 Уорнер-Ламберт Кампэни Derivatives of the 6-arylpyrido [2,3-d] pyrimidines and naphthyridines, parmaceutical composition on base thereof, methods of treatment and inhibition of the tyrosine kinaze receptor cell proliferation and migration
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
NZ508268A (en) * 1998-05-26 2004-02-27 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation

Also Published As

Publication number Publication date
BR0113628A (en) 2003-07-01
CN1275964C (en) 2006-09-20
CN1451005A (en) 2003-10-22
AR033681A1 (en) 2004-01-07
AU9378401A (en) 2002-03-13
KR100571339B1 (en) 2006-04-17
PA8527301A1 (en) 2002-07-30
CA2420286A1 (en) 2002-03-07
MXPA03001821A (en) 2003-06-04
ZA200301079B (en) 2004-05-07
KR20030022422A (en) 2003-03-15
WO2002018380A1 (en) 2002-03-07
PE20020406A1 (en) 2002-05-17
GT200100191A (en) 2002-05-16
JP2004507541A (en) 2004-03-11
AU2001293784B2 (en) 2007-08-30
EP1315726A1 (en) 2003-06-04
JP4141830B2 (en) 2008-08-27

Similar Documents

Publication Publication Date Title
UY26918A1 (en) 7 - PIRIDOPIRIMIDIN OXY (II)
BRPI0512213A (en) method for treating, preventing or ameliorating a disease or disorder; pharmaceutical composition; process for the preparation of a compound; and use of a compound
TR200201057T2 (en) Bicyclic nitrogen heterocycles substituted by heteroalkylamino as inhibitors of P38 protein kinase.
BRPI0417543A (en) quinolines useful in treating cardiovascular disease
NO20083958L (en) Prodrugs of GABA analogs, compositions and uses thereof
CY1107956T1 (en) USE OF 2-AMINOTETRALINE SUBSTITUTES FOR PREVENTIVE TREATMENT OF PARKINS DISEASE
TNSN04165A1 (en) Substituted hydroxyethylamines
DE60229530D1 (en) SUBSTITUTED PIPERAZINE AS MODULATORS OF MELANOCORTINRECEPTOR
AR039219A1 (en) IMIDAZO-REPLACED COMPOUNDS
CY1114728T1 (en) PHARMACEUTICAL FORM INHALATION OF INCLUSIVE PHENATHANOLAMINE PRODUCERS FOR TREATMENT OF RESPIRATORY DISEASES
SE0303180D0 (en) Novel compounds
SE0302232D0 (en) Novel Compounds
BR0116468A (en) Indazolyl-substituted pyrroline compounds as kinase inhibitors
UY29265A1 (en) COMPOUNDS OF 3H-OXAZOLO AND 3H-TIAZOLO (4,5, -D) PIRIMIDIN-2-ONA 3,5- DISUSTITUTED AND 3,5,7-TRISUSTITUIDOS AND ITS PROFESSIONALS
EA200702339A1 (en) SUBSTITUTED AMIDA DERIVATIVES AS AN INHIBITOR PROTEINKINASE INHIBITORS
ATE374029T1 (en) TREATING ALZHEIMER'S DISEASE BY INCREASE CYTIDINE LEVELS IN VIVO
MX2007004183A (en) Benzoimidazole derivatives useful as antiproliferative agents.
BR0311494A (en) New indoles replaced
BRPI0512220A (en) method for treating, preventing or ameliorating a disease or disorder; pharmaceutical composition; process for the preparation of a compound; and use of a compound
DK1346041T3 (en) Therapeutic agents and methods for their use in the treatment of an amyloidogenic disease
BRPI0406883A (en) Compound, pharmaceutical composition, method of treating a disorder, and use of a compound
UY28376A1 (en) THERAPEUTIC AGENTS
MXPA04006184A (en) 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor.
EA200970817A1 (en) DOSAGE FORM CONTAINING 1 {6 - [(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl) oxy] -3-pyridinyl} -2-pyrrolidinone or a salt thereof and a stabilizer WHICH REDUCES HIS DEGRADATION
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141001